Fenofibrate Raw Materials Powder

CAS:49562-28-9

MF:C13H23ClN4O3S

MW:360.83

EINECS:256-376-3

Specification: 99% min Fenofibrate Powder

Sample:Fenofibrate

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Fenofibrate Powder Usage and Synthesis.

Fenofibrate is a lipid-lowering drug, the main mechanism of action is to inhibit HMG-CoA reductase, reduce the synthesis of cholesterol in cells, and thus reduce blood lipid. Fenofibrate is suitable for the treatment of endogenous hypertriglyceridemia and primary hypercholesterolemia, and has been widely used in the United States, France, Japan and other countries, and has become the first choice for the treatment of hyperlipidemia. The efficacy of fenofibrate in lowering TG and increasing HDL-C is significantly better than that of statins. Since simple dyslipidemia in diabetic patients is relatively rare, and its common lipid profile is increased TC, decreased HDL-C, and elevated or normal low-density lipoprotein-cholesterol (LDL-C), fenofibrate has significant clinical efficacy in the treatment of lipid abnormalities in diabetic patients.

Uses of Fenofibrate.

Fenofibrate prevents the occurrence and progression of atherosclerosis by regulating blood lipids. A diabetic atherosclerosis intervention study found that diabetic patients aged 40-65 years who were given fenofibrate at the same time not only had good blood glucose control, but also significantly reduced low density lipoprotein and triglycerides, and angiography also showed that compared with pre-treatment, the mean arterial cavity diameter was reduced less in the fenofibrate treatment group than in the placebo group. These results suggest that fenofibrate therapy can delay the progression of coronary atherosclerotic stenosis. Fenofibrate was also associated with a 24% lower risk of heart attack. In addition, studies have found that fenofibrate can also reduce fibrinogen and inhibit platelet aggregation. Since platelet aggregation and elevated fibrinogen levels are inducible factors for thrombosis, fenofibrate can also prevent thrombosis and has a significant cardiovascular protective effect.

Pharmacological action of Fenofibrate.

1. Lipid regulation effect

Fenofibrate can reduce the total triglyceride (TG) level by 25% to 59%, the high density lipoprotein-cholesterol (HDL-C) level by 1% to 34%, and the total cholesterol (TC) level by 6% to 27%. It is clinically used for the treatment of mixed hyperlipidemia with elevated TG or mainly elevated TG and low HDL-C hyperlipidemia. Fenofibrate has significantly better efficacy than statins in lowering TG and increasing HDL-C. As simple dyslipidemia in diabetic patients is rare, its common lipid profile is increased TC, decreased HDL-C, and elevated or normal low-density lipoprotein cholesterol (LDL-C). Therefore, Fenofibrate has significant clinical efficacy in the treatment of lipid abnormalities in diabetic patients. In addition, due to its different mechanism of action from statins, statins can significantly reduce TC and LDL-C, and the combination of the two can form complementary effects. Therefore, it can be seen that fenofibrate is used in combination with statins such as atorvastatin and simvastatin to adjust the lipid profile of patients with mixed hyperlipidemia.

2. Non-lipid-regulating effect

In addition to regulating blood lipids, fenofibrate also has anti-inflammatory, lower fibrinogen levels and preventive neuroprotective effects, so it is also helpful to reduce the risk of cardiovascular disease. The unique non-lipid-regulating effects of fenofibrate also include increased insulin sensitivity, increased bone mineral density, improved microalbuminuria, and improved hyperuricemia, which can simultaneously improve patients with multiple disorders. Fenofibrate is therefore particularly suitable for regulating dyslipidemia in patients with type 2 diabetes or metabolic syndrome.

3. Anti-tumor effect

Fenofibrate inhibits the expression of tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) monocytes through PPAR-α receptor, and promotes the differentiation and apoptosis of tumor cells.

Preparation method of Bulk Fenofibrate Powder.